Mindray stock fell 2.31 percent while analysts reassessed Q2 growth

Published on 10/08/2026 at 09:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mindray stock was last at CNY 157.60 on October 8, 2026. CITIC Securities called Q2 an inflection point after revenue grew 10.45 percent and overseas sales advanced 13.67 percent.

Mindray, CNE100003G67, Illustration mit AI erstellt.

Mindray stock (ISIN CNE100003G67) was last at CNY 157.60 on Shenzhen on October 8, 2026 at 3:04 p.m. CST, down 2.31 percent from the prior close. The latest analyst assessment centers on second-quarter execution rather than the first-half revenue headline already circulating in the market.

Analysts flag a Q2 inflection

As Sina reported on October 8, 2026, CITIC Securities said Mindray's 2026 second-quarter performance exceeded expectations, with domestic revenue returning to positive growth and overseas business remaining steady. The assessment identifies a longer-cycle performance inflection, while also pointing to foreign-exchange volatility and margin pressure as counter-factors.

The market reaction remains measurable. Mindray's October 8 price of CNY 157.60 stood CNY 3.72 below the prior close of CNY 161.32, while the session range ran from CNY 156.93 to CNY 161.10 and volume reached 5,695,725 shares.

Q2 revenue rose 10.45 percent

According to min.news on October 3, 2026, Mindray generated CNY 9.395 billion in second-quarter revenue, up 10.45 percent year over year. Net profit attributable to shareholders reached CNY 2.467 billion, up 1.10 percent, while operating cash flow was CNY 3.496 billion, an increase of 44 percent.

The comparison matters because first-half net profit fell even as quarterly growth accelerated. First-half revenue reached CNY 17.747 billion, up 6 percent, while net profit attributable to shareholders was CNY 4.797 billion, down 5.37 percent, according to the same report from min.news.

International sales lead growth

International revenue was CNY 9.471 billion in the first half of 2026, up 13.67 percent and representing more than half of total revenue, according to min.news. Emerging businesses added CNY 3.11 billion in first-half revenue, up 19.59 percent, giving investors a second quantified growth engine beyond the core medical-device businesses.

The stock remains below its current 52-week high of CNY 248.98 and above its low of CNY 130.66. Market capitalization stood at CNY 191.1 billion on October 8, 2026, making the gap between improving quarterly momentum and weaker first-half profit the central valuation issue.

Mindray stock stays below its yearly high

Mindray stock was last at CNY 157.60 on the Shenzhen Stock Exchange on October 8, 2026 at 3:04 p.m. CST. The company operates in healthcare and advanced medical equipment, with products spanning patient monitoring, in-vitro diagnostics and medical imaging.